You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.

2nd Annual Perspectives in Malignant Hematology: Novel Practice Exchange

Read Overview

Supported by independent educational grants from CTI Biopharma; GlaxoSmithKline; Incyte; Janssen; Regeneron; Seagen, Inc.

                                                                                                                                                                                                          

CME Activities

  • Do you know the latest approaches to treating chronic leukemias?
    1.50 CME
    1.50 ABIM MOC
    1.50 CE
    1.50 CE
  • What are the latest advances in myelodysplastic syndrome and myeloproliferative neoplasms?
    1.00 CME
    1.00 ABIM MOC
    1.00 CE
    1.00 CE
  • Are you aware of disparities that affect treatment of hematologic malignancies? Dr Edith Mitchell reviews the history and looks at strategies for reducing disparities in care and improving outcomes.
    0.75 CME
    0.75 ABIM MOC
    0.75 CE
    0.75 CE
  • Do you feel confident in applying the latest data to clinical practice? Join our expert panel to hear the latest updates and best practices.
    0.75 CME
    0.75 ABIM MOC
    0.75 CE
    0.75 CE
  • Are you up to date on the latest research on acute leukemias?
    1.75 CME
    1.75 ABIM MOC
    1.75 CE
    1.75 CE
  • Watch experts discuss personalized treatment for patients with T-cell lymphoma.
    0.75 CME
    0.75 ABIM MOC
    0.75 CE
    0.75 CE
  • Did you know that the historical treatment for frontline therapy for stage III/IV classic Hodgkin lymphoma (cHL) has recently changed?
    1.25 CME
    1.25 ABIM MOC
    1.25 CE
    1.25 CE
  • Did you know that we are still making progression in improving outcomes for our patients with non-Hodgkin lymphomas?
    1.25 CME
    1.25 ABIM MOC
    1.25 CE
    1.25 CE
  • Is it time for precision medicine in the treatment of multiple myeloma (MM)?
    1.00 CME
    1.00 ABIM MOC
    1.00 CE
    1.00 CE
  • Is your care team ready to optimize cellular therapies for patients with hematologic malignancies?
    1.25 CME
    1.25 ABIM MOC
    1.25 CE
    1.25 CE
  • Are you up to date on the latest treatment strategies for multiple myeloma?
    2.50 CME
    2.50 ABIM MOC
    2.50 CE
    2.50 CE

Steering Committee

Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP

Steering Committee Chair

Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Courtney D. DiNardo, MD, MSCE
Courtney D. DiNardo, MD, MSCE

Steering Committee Member

Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Christopher Flowers, MD, MS
Christopher Flowers, MD, MS

Steering Committee Member

Chair, Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Steven Horwitz, MD
Steven Horwitz, MD

Steering Committee Member

Associate Attending Physician
Department of Medicine
Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Elias J. Jabbour, MD
Elias J. Jabbour, MD

Steering Committee Member

Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Shaji Kumar, MD
Shaji Kumar, MD

Steering Committee Member

Professor of Medicine
Division of Hematology
Department of Internal Medicine
Mayo Clinic
Rochester, Minnesota

Sandra Kurtin, PhD, ANP-C, AOCN
Sandra Kurtin, PhD, ANP-C, AOCN

Steering Committee Member

Assistant Professor of Clinical Medicine
Adjunct Clinical Assistant Professor of Nursing
University of Arizona
Tucson, Arizona

Kathryn Maples, PharmD, BCOP
Kathryn Maples, PharmD, BCOP

Steering Committee Member

Clinical Pharmacy Specialist
Emory Healthcare
Atlanta, Georgia